Table 2.
Analyses performed on a subset of patients who received neurotoxic antiretrovirals, comparing those who developed antiretroviral toxic neuropathy (ATN) to those who did not
| ATN | No ATN | p | |
|---|---|---|---|
| n | 18 | 35 | |
| Age, y | 41.4 (6.2) | 41.1 (8.3) | .91 |
| Gender, % | .78 | ||
| Male | 67 | 63 | |
| Female | 33 | 37 | |
| Ethnicity, % | .02 | ||
| non-Hispanic white | 22 | 17 | |
| African-American | 11 | 49 | |
| Hispanic | 67 | 34 | |
| HIV risk factor, % | .02 | ||
| Heterosexual sex | 6 | 43 | |
| Homosexual sex | 28 | 26 | |
| IVDU | 61 | 31 | |
| Other/multiple | 6 | 0 | |
| Co-morbidities, % | .72 | ||
| Diabetes Mellitus | 9 | 0 | |
| Alcoholism | 11 | 11 | |
| Renal Failure | 3 | 0 | |
| Cumulative d-drug exposure during study, grams | 120 (160) | 200 (360) | .25 |
| CD4 count at baseline, cells/mm3 | 290 280) | 130 (210) | .02 |
| HIV-1 viral load (copies/ml)* | 3.0 (1.4) | 3.8 (1.5) | .05 |
Values are mean (SD), except where indicated.
*
Value expressed as log base 10.